Topics

Association between the procoagulant pathway and thromboinflammation.

Chronic Inflammation Inflammation Initiation Complex Intercellular Communication & Diseases Cellular Stress

Thromboinflammation describes pathological reinforcement between innate immunity, platelet activation, endothelial responses, and coagulation. Its physiological counterpart, immunothrombosis, forms intravascular scaffolds that help recognize, contain, and destroy pathogens, especially in microvessels. When activation becomes excessive or persistent, the same system drives myocardial infarction, stroke, venous thromboembolism, and organ injury. This concept expands classical coagulation beyond an enzymatic cascade or platelet plug by integrating leukocytes, damage-associated signals, complement, and inflammatory mediators. It also explains why antiplatelet and anticoagulant drugs reduce events but cannot eliminate thrombosis and why intensifying them is constrained by bleeding The procoagulant pathway is therefore embedded in an immune response whose physiological purpose is containment, but whose dysregulation converts local defense into systemic vascular injury[1][2].

Vascular injury or infection releases damage-associated molecular patterns that activate endothelium and innate immune cells. Monocytes can express tissue factor, neutrophils release extracellular traps, platelets provide procoagulant surfaces, and complement amplifies cellular recruitment and coagulation. A convergent model treats clot formation, inflammation, resolution, and wound healing as coordinated responses rather than separate pathways. Antiphospholipid syndrome illustrates pathological convergence: autoantibodies activate endothelium, platelets, and myeloid cells, disturb coagulation and fibrinolysis, promote neutrophil extracellular traps and complement, and can produce both acute thrombosis and chronic occlusive vasculopathy. The mechanism depends on context, flow, vascular bed, and immune trigger Damage signals, complement, antibodies, neutrophil traps, tissue factor, and platelets can enter the loop at different points and create similar clinical thrombosis[1][3][4].

Severe infection provides another application. In COVID-19, activated neutrophils and monocytes interact with platelets and coagulation to form micro- and macrovascular thrombi that contribute to pulmonary and systemic organ dysfunction. More recently, reduced flow was shown to permit IgM engagement of endothelial receptors, followed by platelet recruitment, IgG deposition, classical complement activation, and a self-reinforcing prothrombotic loop; pharmacological complement targeting interrupts this mechanism experimentally. These findings support therapies aimed at inflammation, complement, extracellular traps, or cellular adhesion in addition to conventional antithrombotics. The appeal is to reduce pathological thrombosis while preserving hemostasis, but each pathway also contributes to host defense and repair Mechanism-specific adjuncts could reduce residual events without proportionally increasing bleeding, but only if the selected inflammatory circuit is active in the treated population[2][4][5][6].

The central challenge is patient and pathway selection. Biomarkers of inflammation or coagulation alone do not establish active thromboinflammation, and syndromes such as sepsis, autoimmunity, atherosclerosis, cancer, or venous stasis use different initiating signals. Trials should combine mechanistic markers with vascular imaging and clinical events and should measure infection, bleeding, wound healing, and rebound thrombosis. Timing matters because early immunothrombosis can be protective while late amplification causes injury. Future diagnostics should identify the dominant cellular or complement circuit and determine whether it adds risk beyond established scores. Therapeutics should be evaluated as complements, not automatic substitutes, for antiplatelet or anticoagulant treatment. A clinically useful convergent model must show where interrupting immunity reduces thrombosis without disabling essential hemostatic and antimicrobial functions Serial assays should capture activation and resolution because a single inflammatory or coagulation measurement cannot distinguish protective immunothrombosis from persistent thromboinflammation[1][5][6][7].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-14648C Dexamethasone (Water Soluble)
Dexamethasone (Hexadecadrol) Water Soluble is a water-soluble form of Dexamethasone (HY-14648). Dexamethasone is a glucocorticoid receptor agonist, apoptosis inducer, and a common disease inducer in experimental animals. It can be used to construct models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has the potential to be used in COVID-19 research.(Sale size is the weight of dexamethasone)
Exosomes   Glucocorticoid Receptor   SARS-CoV   Autophagy   Complement System   Mitophagy   Bacterial   Antibiotic  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Coronavirus Infection   Depression   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   Hypertension  
402
HY-14648 Dexamethasone
Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist, apoptosis inducer, and common disease inducer in experimental animals, constructing models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has potential for use in COVID-19 research.
Exosomes   Glucocorticoid Receptor   SARS-CoV   Autophagy   Complement System   Mitophagy   Bacterial   Antibiotic   ADC Payloads  
Metabolic or Endocrine Disease   Prostate Cancer   Pancreatic Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Autoimmune Disease   Digestive System Inflammation   Cardiovascular Disease   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
402
HY-B0579 Cyclosporin A
Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.

Source: the fungus Beauveria nivea.

Molecular Glues   Complement System   Antibiotic   Cyclophilin  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection   Lung Fibrosis  
214
HY-L001P Bioactive Compound Library Plus
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype. MCE owns a unique collection of 32,925 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc. Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.

General Bioactive Screening Libraries

131
HY-L022P FDA-Approved Drug Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,663 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Drug Repurposing Series

97
HY-L021P Natural Product Library Plus
Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. Natural sources may lead to basic research on potential bioactive components for commercial development as lead compounds in drug discovery. Nature has been a source of medicinal agents for thousands of years, and an impressive number of modern drugs have been isolated from natural sources, many based on their use in traditional medicine. With the development of new molecular targets, there is an increasing demand for novel molecular diversity for screening. Natural products will play a crucial role in meeting this demand through the continued investigation of world’s bio-diversity, much of which remains unexplored. MCE provides a unique collection of 6,400 natural compounds that contains Saccharides and Glycosides, Phenylpropanoids, Quinones, Flavonoids, Terpenoids and Glycosides, Steroids, Alkaloid, Phenols, Acids and Aldehydes. Natural Product Library Plus, with more powerful screening capability, further complements Natural Product Library (HY-L021) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Natural Product Screening Libraries

92
HY-L035P Drug Repurposing Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety, which are suitable for drug repurposing. MCE Drug Repurposing Compound Library plus contains 6,142 approved and passed phase I clinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE Drug Repurposing Compound Library plus, with more powerful screening capability, further complement MCE Drug Repurposing Compound Library (HY-L035) by adding some compounds with low solubility or stability (Part B) to this library. All those supplementary compounds are supplied in powder form.

Drug Repurposing Series

89
HY-L026P Clinical Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 3,298 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Drug Repurposing Series

86
HY-L014 NF-κB Signaling Compound Library
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. MCE owns a unique collection of 1,801 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Signaling Pathway Targeting Libraries

85
HY-L136 Coagulation and Anti-coagulation Compound Library
Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation. Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process. MCE supplies a unique collection of 1,525 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Signaling Pathway Targeting Libraries

85
HY-L036P Covalent Screening Library Plus
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 6,121 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc. MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Structure Classified Libraries

83
HY-L088 Angiogenesis-Related Compound Library
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer). MCE offers a unique collection of 3,660 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Signaling Pathway Targeting Libraries

83
HY-L156 Autoimmune Disease Compound Library
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 1,040 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Disease Focused Libraries

83
HY-L161 Cytokine Inhibitors Library
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases. MCE designs a unique collection of 1,416 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

Signaling Pathway Targeting Libraries

83
HY-L174 Macrophage Related Compound Library
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Compound Characteristic Classified Libraries

83
HY-L193 PBCRBS Traditional Chinese Medicine Compound Library
Since ancient times, promoting blood circulation for removing blood stasis (PBCRBS) has been one of the most popular research contents in the area of traditional Chinese medicine (TCM) and integrated medicine. Rhizoma, Persicae Semen, Carthami Flos, Curcumae Longae Rhizoma and so on are common TCM with PBCRBS characteristic. Studies have shown that the mechanism of action of PBCRBS TCM is to promote blood circulation (improving cardiovascular and cerebrovascular functions, physical and chemical properties of blood, platelet and coagulation system and other physiological functions) and remove blood stasis (anti-myocardial ischemia, cerebral ischemia, inhibition of platelet aggregation, anti-coagulation, anti-thrombosis, etc.). Not only that, PBCRBS TCM has anti-infection, inhibit inflammation, regulate immune function, inhibit immune response, inhibit abnormal tissue proliferation and other functions. Therefore, PBCRBS TCM has high research value in all- field disease research fields. MCE can supply 1,006 monomer component from more than a hundred sources of PBCRBS TCM, which can be used in TCM studies, drug development and mechanism-based studies.
83
HY-L197 Vitamin Compound Library
Vitamins are a category of trace organic compounds essential for maintaining normal physiological functions in living organisms. They are classified into fat-soluble and water-soluble vitamins. Fat-soluble vitamins play a role in maintaining vision, bone health, reproductive functions, and blood coagulation. Water-soluble vitamins are involved in energy metabolism, nervous system function, and cellular repair processes. Most vitamins cannot be synthesized by the organism and must be obtained through diet. In recent years, vitamins and their derivatives have become increasingly important in the field of drug development due to their extensive physiological activities. Additionally, vitamins and their derivatives can be used to construct research platforms for vitamin metabolism, which helps to delve into the metabolic pathways and dynamic changes of vitamins within the body and aids in identifying new biomarkers for certain diseases. MCE included 136 vitamins and their derivatives, including Vitamin A, Vitamin B, Vitamin D, etc., which is a good tool for studying vitamin metabolism.
83
HY-L207 Mass Spectrometry Human Endogenous Metabolite Library
Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms. MCE can provide 661 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

Metabolism Focused Libraries

83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L237 Pattern Recognition Receptors Library
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions. MCE has cataloged 338 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.
83
HY-17567A Heparin sodium salt
Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.
Exosomes   Thrombin   Factor Xa   Autophagy  
Cancer   Cardiovascular Disease  
62
HY-Y0320C Dimethyl sulfoxide
Dimethyl sulfoxide (DMSO) is an aprotic solvent that can dissolve water-insoluble therapeutic and toxic agents. Dimethyl sulfoxide (DMSO) has a strong affinity for water and has the ability to rapidly penetrate or enhance the penetration of other substances through biological membranes. Dimethyl sulfoxide also has potential free radical scavenging and anticholinesterase effects and may affect coagulation activity. Dimethyl sulfoxide also induces histamine release from mast cells but is thought to have low systemic toxicity.
Low endotoxin, can be used in various biochemical experiments such as drug dissolution.
Environmental Pollutants   Cholinesterase (ChE)   Bacterial  
Inflammation or Immune System Disease   Breast Cancer  
61
HY-101502A SB290157 trifluoroacetate
SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.
Complement System  
Leukemia/Lymphoma/Myeloma   Autoimmune Disease  
36
HY-D0836 EDTA dipotassium dihydrate
EDTA dipotassium dihydrate is a metal ion chelator that forms stable and water-soluble chelates with a variety of metal ions. EDTA dipotassium is commonly used as a blood anticoagulant, which can effectively prevent blood coagulation and maintain the morphology and function of cells in blood samples. In the industrial field, EDTA dipotassium can be used to remove the adverse effects of metal ions and prevent oxidation and deterioration caused by metal ions.
DNA/RNA Synthesis  
33
HY-12821 AEBSF hydrochloride
AEBSF hydrochloride is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.
Thrombin   Influenza Virus   Ser/Thr Protease  
Viral Infection  
20
HY-50903 Rivaroxaban
Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
Factor Xa  
Pancreatic Cancer   Viral Infection   Cardiovascular Disease  
16
HY-110136 PMX 205
PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.
Complement System  
Autoimmune Disease  
15
HY-50667 Apixaban
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
Factor Xa  
Pancreatic Cancer   Viral Infection   Cardiovascular Disease   SARS-CoV-2 Infection  
13
HY-127105 Iptacopan
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).
Complement System  
Metabolic or Endocrine Disease   Autoimmune Disease  
13
HY-15664 Bivalirudin TFA
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others.
Thrombin   Interleukin Related   RSV  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
11
HY-P0019A Z-Gly-Gly-Arg-AMC acetate
Z-Gly-Gly-Arg-AMC acetate is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm).
Fluorescent Dye   Thrombin  
11
HY-P1929 Bivalirudin
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others.
Thrombin   Interleukin Related   RSV  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
11
HY-P0019 Z-Gly-Gly-Arg-AMC
Z-Gly-Gly-Arg-AMC is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm).
Fluorescent Dye   Thrombin  
Blood or Cardio-cerebrovascular Disease  
11
HY-17567 Heparin
Heparin is a highly sulfated glycosaminoglycan,that is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. Heparin significantly inhibits exosome-cell interactions.
Exosomes   Thrombin   Autophagy   Endogenous Metabolite   Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease   Coronavirus Infection   Bacterial Infection  
11
HY-D0199 Adenosine 5'-diphosphate disodium
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis.
Endogenous Metabolite  
Cardiovascular Disease  
10
HY-B0686A Eptifibatide monoacetate
Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
Integrin  
Blood or Cardio-cerebrovascular Disease  
9
HY-B0686B Eptifibatide acetate
Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
Integrin  
Blood or Cardio-cerebrovascular Disease  
9
HY-15526 PSI-697
PSI-697 is an oral P-selectin inhibitor with an IC50 of 125 μM.
P-selectin  
Cancer  
9
HY-10264 Edoxaban
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research.
Factor Xa   Thrombin  
Cancer   Viral Infection   Cardiovascular Disease   SARS-CoV-2 Infection  
9
HY-B0686 Eptifibatide
Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
Integrin  
Blood or Cardio-cerebrovascular Disease  
9
HY-106178 PMX-53
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects.
Complement System  
Cancer   Autoimmune Disease   Cardiovascular Disease  
9
HY-N0684 Vitamin K1
Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.
Others  
Cancer   Cardiovascular Disease   Glucose Metabolism  
8
HY-114164 Thrombin (MW 37kDa)
Thrombin (MW 37kDa) is a Na+-activated, allosteric serine protease that plays opposing functional roles in blood coagulation. Thrombin recognition sequence and can be used to digest GST-tagged proteins.
Thrombin  
Neurological, Eye or Ear Disease  
8
HY-10163 Dabigatran
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
Thrombin  
Cancer   Blood or Cardio-cerebrovascular Disease  
7
HY-N0762 Isobavachin
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease.
Cytochrome P450   UGT   p38 MAPK   NF-κB   NO Synthase   COX   Fc Receptor (FcR)   RANKL/RANK   Keap1-Nrf2   Reactive Oxygen Species (ROS)   Apoptosis   Autophagy  
Prostate Cancer   Liver Cancer   Glioma   Allergy   Acute Myeloid Leukemia   Alzheimer's Disease   Antioxidant Agent   Osteoporosis   Liver Injury   Osteoarthritis   Rheumatoid Arthritis  
6
HY-N4314 Scutellarein tetramethyl ether
Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive compound extracted from Eupatorium odoratum. Scutellarein tetramethyl ether exhibits anti-inflammatory, antibacterial, pro-coagulant, and anti-tumor activities. Scutellarein tetramethyl ether exerts its anti-inflammatory effects by modulating the NF-κB pathway and regulates bacterial resistance through the inhibition of efflux pumps. Additionally, Scutellarein tetramethyl ether accelerates coagulation time via the endogenous coagulation pathway. Studies have shown that Scutellarein tetramethyl ether can effectively inhibit the growth of the liver cancer cell line HepG2 (IC50= 20.08 μg/mL).
Bacterial   COX   NO Synthase   NF-κB  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Obesity   Rheumatoid Arthritis  
5
HY-137431 Asundexian
Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM.
Factor Xa  
Blood or Cardio-cerebrovascular Disease  
5
HY-17627 Avacopan
Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
Complement System  
Autoimmune Disease  
5
HY-116282 Dextran sulfate sodium salt (MW 5000)
Dextran sulfate sodium salt (DSS) (MW 5000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt (DSS) with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 5000) is an inhibitor of complement and coagulation pathways, and belongs to the glycosaminoglycans (GAG) family. Dextran sulfate sodium salt (MW 5000) acts as an anticoagulant, antiviral, and anti-lipemic agent. Dextran sulfate sodium salt (DSS) stops HIV-1 virus adsorption to host cells. Dextran sulfate sodium salt (MW 5000) prevents NK cell-mediated cytotoxicity. Dextran sulfate sodium salt (MW 5000) inhibits instant blood-mediated inflammatory reaction (IBMIR).
HIV   Complement System   Apoptosis  
Infection   Inflammation or Immune System Disease  
5
HY-106139 Bimosiamose
Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects.
P-selectin   L-Selectin   E-Selectin  
Inflammation or Immune System Disease   SARS-CoV-2 Infection  
4
HY-B0597 Fondaparinux sodium
Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
Factor Xa  
Cancer   Viral Infection   Cardiovascular Disease  
4
HY-B2123 Lactose
Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions.
Environmental Pollutants   ERK   Interleukin Related   Endogenous Metabolite   NF-κB  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity  
4
HY-10274 Dabigatran etexilate
Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
Thrombin  
Cardiovascular Disease   SARS-CoV-2 Infection  
4
HY-122542B PPACK TFA
PPACK TFA is a potent, peptidic inhibitor targeting thrombin and granzyme GZMK. PPACK TFA specifically blocks the activities of thrombin and GZMK, thereby inhibiting thrombin-mediated PAR-1 cleavage, as well as downstream inflammatory and procoagulant signaling pathways. Through stabilizing IκB proteins, blocking NF-κB activation and reducing systemic levels of proinflammatory/procoagulant biomarkers, PPACK TFA exerts multiple effects including anti-inflammatory, antithrombotic, barrier repair, and inhibition of atherosclerotic plaque progression. PPACK TFA binds to platelets without interference from kininogen, effectively limiting acute thrombus growth and reducing eosinophil infiltration and goblet cell hyperplasia in asthma models. PPACK TFA is an important tool molecule for investigating the mechanisms of atherosclerosis, asthma and related thromboinflammatory diseases.
Protease Activated Receptor (PAR)   Thrombin   NF-κB  
Allergic Asthma   Atherosclerosis and Inflammation   Atherosclerosis  
4
HY-P9914 Eculizumab
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies.

Species: Human

Complement System  
CNS Infection   Visual System Disease   Blood Disease   SARS-CoV-2 Infection  
4
HY-P1036A Compstatin TFA
Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
Complement System  
3
HY-145237 BM213
BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury.
Complement System   Apoptosis   Reactive Oxygen Species (ROS)  
Cancer  
3
HY-32350 Ercalcitriol
Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
VD/VDR   Drug Metabolite   Endogenous Metabolite  
Metabolic or Endocrine Disease  
3
HY-P99979 Rat IgG1 kappa, Isotype Control
Rat IgG1 kappa, Isotype Control, a rat monoclonal antibody, is an isotype control for Rat IgG1κ antibody.
Fc Receptor (FcR)  
Inflammation or Immune System Disease  
3
HY-P1036 Compstatin
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
Complement System  
3
HY-P0074 GPRP
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor). GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases.
Thrombin  
Blood or Cardio-cerebrovascular Disease  
3
HY-P99444 Astegolimab
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research.

Species: Human

Interleukin Related   MDM-2/p53   NF-κB  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
3
HY-P99037 Nipocalimab
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases.

Species: Human

Fc Receptor (FcR)  
Myasthenia gravis   Rheumatoid Arthritis  
3
HY-17567C Heparin sodium salt (MW 15kDa)
Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa.
Thrombin   Factor Xa   Autophagy  
Cancer   Cardiovascular Disease  
3
HY-107911 Protamine sulfate
Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer.
Thrombin  
Metabolic or Endocrine Disease  
3
HY-P3252AS Pegcetacoplan-13C3,15N TFA
Pegcetacoplan-13C3,15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
Isotope-Labeled Compounds   Complement System  
Inflammation or Immune System Disease  
2
HY-103358 KF38789
KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM.
P-selectin  
Inflammation or Immune System Disease  
2
HY-N0353 Curdione
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
Ferroptosis   Apoptosis   Reactive Oxygen Species (ROS)   Autophagy   Glutathione Peroxidase   Keap1-Nrf2   Heme Oxygenase (HO)   TGF-β Receptor   Indoleamine 2,3-Dioxygenase (IDO)  
Colorectal Cancer   Pancreatic Cancer   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Lung Fibrosis  
2
HY-125856 Milvexian
Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the Ki of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study.
Factor Xa  
Blood or Cardio-cerebrovascular Disease  
2
HY-P9934 Abciximab
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.

Species: Human

Integrin  
Blood or Cardio-cerebrovascular Disease  
2
HY-P99644 ACT017
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke.

Species: Human

Glycoprotein VI  
Blood or Cardio-cerebrovascular Disease  
2
HY-N9481 Lipoteichoic acid
Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin.

Source: Staphylococcus aureus

Complement System   Autophagy   mTOR   Akt   PI3K   ERK   Interleukin Related  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
2
HY-P99227 Caplacizumab (His Tag)
Caplacizumab (His Tag) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab (His Tag) inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab (His Tag) inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab (His Tag) can be used for the research of thrombotic thrombocytopenic purpura (TTP).

Species: Human

Integrin   Transmembrane Glycoprotein  
Blood or Cardio-cerebrovascular Disease  
2
HY-112624 Dextran
Dextran (Dextran 40) has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease  
2
HY-P3252A Pegcetacoplan acetate
Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
Complement System  
Inflammation or Immune System Disease  
2
HY-125859 Peroxidase, Horseradish
Peroxidase, Horseradish actively involves in oxidizing reactive oxygen species, innate immunity, hormone biosynthesis and pathogenesis of several diseases.
Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
2
HY-141567 Pseudouridine 5'-triphosphate
Pseudouridine 5'-triphosphate (Pseudo-UTP) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate can be used for the research of vaccinia virus infection.
DNA/RNA Synthesis  
Viral Infection  
1
HY-P1505 C3a (70-77)
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
Complement System  
Inflammation or Immune System Disease  
1
HY-N0620 Mulberroside C
Mulberroside C is one of the main bioactive components in white mulberry (Morus alba L.). Mulberroside C exhibits antiplatelet, antiviral and neutrophil-regulating activities, and binds to EV-A71 VP1 with a Kd value of 1.289 nM. Mulberroside C reduces the phosphorylation level of ERK, promotes the phosphorylation of IP3RI at the Ser1756 site, and decreases calcium influx and calcium mobilization. Mulberroside C inhibits the expression of P-selectin (P-selectin). Mulberroside C upregulates the cyclic nucleotide signaling pathway in human platelets. Mulberroside C binds to IL-23R, upregulates the expression of G-CSF, GM-CSF and RASGRP1, and activates the RAS/ERK signaling pathway. Mulberroside C promotes neutrophil maturation, accelerates the recovery of leukopenia, and enhances the antibacterial activity of neutrophils. Mulberroside C inhibits the replication of hepatitis C virus in replicon cells. Mulberroside C prevents the uncoating and genome release of EV-A71, and inhibits the synthesis of viral proteins and RNA. Mulberroside C can be used in studies related to thrombosis-mediated cardiovascular diseases, chemotherapy- and radiotherapy-induced leukopenia, hepatitis C virus infection, and hand, foot and mouth disease.
HCV   Enterovirus   PERK   Calcium Channel   P-selectin   HCN Channel   Ras   ERK   DNA/RNA Synthesis  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Hepatitis C Virus Infection   Staphylococcus Aureus Infection  
1
HY-P991117 Amrecibart
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).

Species: Human

Factor Xa  
Blood or Cardio-cerebrovascular Disease  
1
HY-P991124 Cenvacibart
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases.

Species: Human

Factor XI  
Blood or Cardio-cerebrovascular Disease  
1
HY-N6689 Destruxin A
Destruxin A is a fungal cyclopeptide with insecticidal and antiviral activities. Destruxin A has a certain inhibitory effect on leukemia cells in vitro. Destruxin A can also specifically inhibit the innate immune response of Drosophila melanogaster, making the flies more susceptible to bacterial infections.

Source: Metarhizium anisopliae

Insecticide   Bacterial  
Cancer   Infection   Inflammation or Immune System Disease  
1
HY-P99263 Inclacumab
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion.

Species: Human

P-selectin  
Blood or Cardio-cerebrovascular Disease  
1
HY-P1505A C3a (70-77) TFA
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
Complement System  
Inflammation or Immune System Disease  
1
HY-D1056H Lipopolysaccharides, from S. marcescens
Lipopolysaccharides, from S. marcescens (Serratia marcescens) are lipopolysaccharide endotoxins and TLR-4 activators derived from Serratia marcescens, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from S. marcescens exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from S. marcescens induce NF-κB activation in mouse cells via Toll-like receptor (TLR4)/MD-2. The lipopolysaccharides of S. marcescens can induce apoptosis in host immune cells, thereby suppressing the host's innate immunity.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-P9987 Crizanlizumab
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.

Species: Human

P-selectin  
Blood or Cardio-cerebrovascular Disease  
1
HY-P4245 D-Pro-Phe-Arg-Chloromethylketone
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.
Factor Xa   Kallikrein  
Neurological, Eye or Ear Disease   Cardiovascular Disease  
1
HY-141567A Pseudouridine 5'-triphosphate trisodium solution (100 mM)
Pseudouridine 5'-triphosphate (Pseudo-UTP) trisodium solution (100 mM) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate trisodium solution (100 mM) enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate trisodium solution (100 mM) can be used for the research of vaccinia virus infection.
DNA/RNA Synthesis  
Viral Infection  
1
HY-P99300 Ligelizumab
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma).

Species: Human

Fc Receptor (FcR)  
Allergic Asthma   Urticaria  
1
HY-109509 Enoxaparin
Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19.
Factor Xa   Thrombin   SARS-CoV  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Viral Infection   Cardiovascular Disease  
1
HY-P99014 Cusatuzumab
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML).

Species: Human

Fc Receptor (FcR)   NF-κB  
Inflammation or Immune System Disease   Acute Myeloid Leukemia  
1
HY-P99044 Sabatolimab
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.

Species: Human

Tim3  
Inflammation or Immune System Disease   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
1
HY-W041892 Dimethyl itaconate
Dimethyl itaconate induces innate immune memory (trained immunity), and exhibits immunomodulatory property. Dimethyl itaconate inhibits the activation of microglia, reduces the neuroinflammation and synaptic structural damage. Dimethyl itaconate regulates the composition of intestinal flora.
Reactive Oxygen Species (ROS)  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
1
HY-D1056B3 Lipopolysaccharides, from Klebsiella pneumoniae
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct Acute Lung Injury Model.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-P701216 Prothrombin Protein, Human (HEK293, His)
Prothrombin or factor II is a key protein in a variety of physiological processes. The serine protease thrombin, derived from prothrombin, cleaves the bond behind arginine and lysine residues, converting fibrinogen to fibrin. Prothrombin Protein, Human (HEK293, His) is the recombinant human-derived Prothrombin protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Human; Source: HEK293

Enzymes & Regulators Hydrolases (EC 3)

1
HY-P74375 C2/Complement C2 Protein, Human (HEK293, His)
C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, His) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 2

1
HY-P81185 C5b-9 Antibody
C5b-9 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to C5b-9.

Host: Rabbit; Reactivity: Human, Rat

Polyclonal Antibodies Primary Antibodies

1
HY-P82008 F2 Antibody (YA1753)
F2 Antibody (YA1753) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Prothrombin.

Host: Rabbit; Reactivity: Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

1
HY-15371G Forskolin (GMP)
Forskolin (Coleonol) (GMP) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase. Forskolin (GMP) is also an inducer of intracellular cAMP formation. Forskolin (GMP) induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin (GMP) exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin (GMP) also induces autophagy.
Adenylate Cyclase   FXR   Autophagy   PKC  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P11791 nNIF peptide
nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis.
Endogenous Metabolite  
Coronavirus Infection  
/
HY-N0684S1 Vitamin K1-d4
Vitamin K1-d4 is the deuterium labeled Vitamin K1. Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.
Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease  
/
HY-D2706 Cy3 Dextran (MW 3000)
Cy3 Dextran (MW 3000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm).
Fluorescent Dye  
/
HY-N10271 SCH 38519
SCH 38519 is a platelet aggregation inhibitor. SCH 38519 inhibits thrombin-induced aggregation of human platelets with an IC50 of 68 μg/mL. SCH 38519 is also active against Gram-positive and Gram-negative bacteria .

Source: Thermomonospora sp. Taxonomy

Bacterial  
Infection  
/
HY-N0353R Curdione (Standard)
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
Reference Standards   Ferroptosis   Apoptosis   Reactive Oxygen Species (ROS)   Autophagy   Glutathione Peroxidase   Keap1-Nrf2   Heme Oxygenase (HO)   TGF-β Receptor   Indoleamine 2,3-Dioxygenase (IDO)  
Cancer  
/
HY-P5528 2Abz-SLGRKIQIK(Dnp)-NH2
2Abz-SLGRKIQIK(Dnp)-NH2 is a biological active peptide. (This peptide is a second complement component (C2), the physiological substrate for the proenzyme Cls, first complement component. The complement system is a central component of host defense but can also contribute to the inflammation seen in pathological conditions. The C1s protease of the C1 complex initiates the host defense pathway. This peptide employs 2Abz/Dnp FRET pair for quantitation of complement enzyme activity.)
Others  
/
HY-N1208 Spiradine F
Spiradine F is a main alkaloidal component of spiraea japonioa L. fil. Spiradine F derivative can inhibit platelet-activating factor (PAF)-induced platelet aggregation.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-121377 Epiyangambin
Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells).
Platelet-activating Factor Receptor (PAFR)  
Inflammation or Immune System Disease  
/
HY-Y0320E Dimethyl sulfoxide (suitable for HPLC)
Dimethyl sulfoxide (suitable for HPLC) is an aprotic solvent that can dissolve water-insoluble therapeutic and toxic agents. Dimethyl sulfoxide (DMSO) has a strong affinity for water and has the ability to rapidly penetrate or enhance the penetration of other substances through biological membranes. Dimethyl sulfoxide also has potential free radical scavenging and anticholinesterase effects and may affect coagulation activity. Dimethyl sulfoxide also induces histamine release from mast cells but is thought to have low systemic toxicity. Dimethyl sulfoxide (suitable for HPLC) is suitable for HPLC.
Cholinesterase (ChE)   Bacterial  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P1536 Thrombin Receptor Activator for Peptide 5 (TRAP-5)
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).
Protease Activated Receptor (PAR)  
Blood or Cardio-cerebrovascular Disease  
/
HY-113958S Difethialone-d4
Difethialone-d4 (Baraki-d4; LM 2219-d4) is the deuterium labeled Difethialone (HY-113958). Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts.
Isotope-Labeled Compounds   VD/VDR  
/
HY-126944 2-Aminobenzanilide
2-Aminobenzamide is a neutral and stable compound used as fluorescent tag, numerously in Glycan analysis. 2-aminobenzamide acts as the starting material for several important reactions like Bargellini reaction as an competent ambident nucleophile. Specifically 2-aminobenzamide and its derivatives are used in the blood coagulation cascade.
Biochemical Assay Reagents  
Cancer  
/
HY-P4576 Methoxycarbonyl-D-Nle-Gly-Arg-pNA
Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa).
Factor Xa  
/
HY-P10868A Pegtarazimod TFA
Pegtarazimod TFA (RLS-0071 TFA) is a dual-target anti-inflammatory peptide that exerts its effects by simultaneously regulating the complement system and neutrophil-associated inflammatory pathways. Pegtarazimod TFA reduces ROS production both in vitro and in vivo, and decreases the level of neutrophil elastase, a marker of neutrophil extracellular traps (NETs), in vivo, thereby alleviating inflammatory responses. Pegtarazimod TFA significantly improves the survival rate of mice in multiple in vivo models of acute graft-versus-host disease (aGVHD). Pegtarazimod TFA inhibits the activation of the C1 complex, reduces the herpes zoster-like spread of herpes simplex virus type 1 skin infection, and improves the survival rate of infected mice. Pegtarazimod TFA can be used in research related to acute graft-versus-host disease, acute pulmonary diseases, and skin herpes simplex virus type 1 infection.
Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   HSV Infection  
/
HY-P990376 Anti-Complement C5aR1 Antibody
Anti-Complement C5aR1 Antibody is a human recombinant antibody expressed in CHO cells, targeting C5AR/C5AR1 /C5R1. Anti-Complement C5aR1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.4 kDa. The isotype control for Anti-Complement C5aR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-17627S1 Avacopan-d4
Avacopan-d4 (CCX168-d4) is the deuterium labeled Avacopan (HY-17627). Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
Isotope-Labeled Compounds   Complement System  
Inflammation or Immune System Disease  
/
HY-NP216 PA-IIL
PA-IIL (LecB) is a lectin produced by Pseudomonas aeruginosa. PA-IIL binds to glycosylated β1-integrin, fucose-containing glycosphingolipids, fucosylated/mannosylated neutrophil glycoconjugates, and pre-formed neutrophil extracellular traps. PA-IIL disrupts host defenses: it creates favorable conditions for Pseudomonas aeruginosa infection and dissemination by modulating the bactericidal activity of neutrophils, impairing the trafficking and recruitment of immune cells, and compromising the repair capacity of epithelial barriers. PA-IIL can be used in studies related to Pseudomonas aeruginosa infection.
Integrin   Endogenous Metabolite   Bacterial  
Pseudomonas Aeruginosa Infection  
/
HY-P3235 E-76
E-76 is a peptide with anticoagulant activity. E-76 inhibits blood coagulation by specifically binding to exogenous coagulation factor VIIa (FVIIa). E-76 can be used to study blood coagulation-related diseases.
Factor VIIa  
/
HY-B0686BR Eptifibatide acetate (Standard)
Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
Reference Standards   Integrin  
Blood or Cardio-cerebrovascular Disease  
/
HY-W014632S 4-Trifluoromethylsalicylic acid-13C6
4-Trifluoromethylsalicylic acid-13C6 is the 13C labeled 4-Trifluoromethylsalicylic acid. 4-Trifluoromethylsalicylic acid is a platelet aggregation inhibitor.
Isotope-Labeled Compounds  
/
HY-B1192S Estradiol benzoate-d3
Estradiol benzoate-d3 is the deuterium labeled Estradiol benzoate. Estradiol Benzoate (β-Estradiol 3-benzoate), a proagent of estradiol, acts as a steroid sex hormone. It exhibits mild anabolic and metabolic properties, and increases blood coagulability.
Estrogen Receptor/ERR  
Neurological, Eye or Ear Disease  
/
HY-18763S Indobufen-d5
Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.
Isotope-Labeled Compounds   COX  
Blood or Cardio-cerebrovascular Disease  
/
HY-NP0194B C1q Protein (rabbit)
C1q Protein (rabbit) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rabbit) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-15284S3 Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
Isotope-Labeled Compounds   P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P11868 PADI4_3
PADI4_3 is a substrate-competitive and selective PADI4 inhibitor with an IC50 of 56 nM. PADI4_3 blocks citrullination of histone H3 and reduces the formation of neutrophil extracellular traps. PADI4_3 can be used in research related to autoimmune diseases and cancers.
Protein Arginine Deiminase  
Cancer   Autoimmune Disease  
/
HY-N7955 23-O-Acetylcimigenol-3-O-α-L-arabinopyranside
23-O-Acetylcimigenol-3-O-α-L-arabinopyranside (Compound 1) is a triterpene glycoside found in the rhizomes of Cimicifuga heracleifolia.23-O-Acetylcimigenol-3-O-α-L-arabinopyranside does not inhibit the classical pathway of the complement system.
Others  
/
HY-N19128 Pulchinenoside J
Pulchinenoside J is a lupane-type triterpenoid saponin and a complement system inhibitor that acts via the classical pathway. Pulchinenoside J can be isolated from the roots of Pulsatilla chinensis.
Complement System  
/
HY-173418 Carbaprostacyclin-biotin
Carbaprostacyclin-biotin (cPGI-biotin; Carbacyclin-biotin) is a biotin-bound Carbacyclin (Carbaprostacyclin) (HY-112322). Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.
Prostaglandin Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-113459S Prostaglandin F1a-d9
Prostaglandin F1a-d9 is the deuterium labeled Prostaglandin F1a. Prostaglandin F1a is an endogenous metabolite and a cyclooxygenase product with platelet activity inhibitory effects. Prostaglandin F1a can be used as a marker in coagulation-related studies.
Isotope-Labeled Compounds   COX   Prostaglandin Receptor   Endogenous Metabolite  
/
HY-N0712R Typhaneoside (Standard)
Typhaneoside (Standard) is the analytical standard of Typhaneoside. This product is intended for research and analytical applications. Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function.
Reference Standards   Autophagy  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-182607 SA buffer, 1×, pH 7.4
SA buffer, 1×, pH 7.4, is mainly composed of sodium chloride, calcium chloride, magnesium chloride, sodium bicarbonate, etc. It is the most commonly used reagent for diluting serum and other samples in immunotoxicology experiments, and is used for complement determination experiments, etc.
Biochemical Assay Reagents  
/
HY-124371 Amentoflavone hexaacetate
Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects.
Phosphodiesterase (PDE)  
Blood or Cardio-cerebrovascular Disease  
/
HY-P99815 Pegacaristim
Pegacaristim is a monoclonal antibody with thrombopoietic activity. Pegacaristim can promote generation of platelets.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P2444 Platelet factor 4 (59-70)
Platelet factor 4 (59-70) is a polypeptide, which is composed of platelets and megakaryocytes. Platelet factor 4 (59-70) stimulates dog mastocytoma cells, promotes the release of histamine and leukotrienes.
Others  
Inflammation or Immune System Disease  
/
HY-P991305 AGEN-1571
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-P3052 RGDV
RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect.
Others  
/
HY-P2291 Beta-defensin 103 isoform X1, pig
Beta-defensin 103 isoform X1, pig is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.
Bacterial  
Inflammation or Immune System Disease  
/
HY-15283AS1 (±)-Clopidogrel-d4
(±)-Clopidogrel-d4 ((±)-Clopidogrelum-d4) is the deuterium labeled (±)-Clopidogrel (HY-107867). (±)-Clopidogrel is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel has anti-inflammatory effects.
Isotope-Labeled Compounds   P2Y Receptor  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-N12265 Versicolactone B
Versicolactone B is a sesquiterpene that can be isolated from Viola yedoensis. Versicolactone B exhibits anti-complement activity against the classical pathway and the alternative pathway.
Others  
Inflammation or Immune System Disease  
/
HY-P3151A Gliadin p31-43 TFA
Gliadin p31-43 TFA is an undigested gliadin peptide. Gliadin p31-43 TFA induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 TFA can be used for celiac disease research.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P990377 Anti-Complement Factor B Antibody
Anti-Complement Factor B Antibody is a CHO-expressed human antibody that targets Complement Factor B. The Anti-Complement Factor B Antibody carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-158485 M5 glycan (Man5)
M5 glycan (Man5) (Mannose-5 N-linked oligosaccharide; Oligomannose 5 glycan) is an N-linked glycan on glycoproteins on glycoproteins. M5 glycan (Man5) enhances antibody-dependent cell-mediated cytotoxicity and reduces complement-dependent cytotoxicity.
Biochemical Assay Reagents  
/
HY-P5372 Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2
Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2, a bioactive peptide, is a selective Protease activating receptor 1 (PAR-1) agonist over PAR-2. PAR-1 belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type'.
Protease Activated Receptor (PAR)  
/
HY-118779 Rhazimine
Rhazimine is an indole alkaloid that is a dual inhibitor of arachidonic acid metabolism and platelet activating factor-induced platelet aggregation.
Platelet-activating Factor Receptor (PAFR)  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-15284S2 Prasugrel-d4
Prasugrel-d4 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-N21519 8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon
8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon is a phenalenone derivative found in the aerial parts of Helicteres angustifolia. 8-Acetyl-9-hydroxy-3-methoxy-7-methyl-1-phenalenon exhibits moderate anti-complement activity against the classical pathway and weak activity against the alternative pathway.
Complement System  
Inflammation or Immune System Disease  
/
HY-113958S1 Difethialone-d4-1
Difethialone-d4-1 (LM-2219-d4-1) is the deuterium labeled Difethialone (HY-113958). Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts.
Isotope-Labeled Compounds   VD/VDR  
/
HY-N7700B L-Guluronic acid
L-Guluronic acid is a coagulation factor X inhibitor. L-Guluronic acid can replace L-Iduronic acid (HY-135197) in the anticoagulant pentasaccharide of heparin-like substances, while retaining the inhibitory activity against factor Xa. L-Guluronic acid can be used in the research of diseases with coagulation disorders such as deep vein thrombosis and pulmonary embolism.

Source: alginic acid

Factor Xa  
Blood Disease  
/
HY-W743984 Melagatran-d11
Melagatran-d11 is the deuterium labeled Melagatran (HY-129056). Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion.
Isotope-Labeled Compounds   Thrombin  
Blood or Cardio-cerebrovascular Disease  
/
HY-N4314R Scutellarein tetramethyl ether (Standard)
Scutellarein tetramethyl ether (Standard) is the analytical standard of Scutellarein tetramethyl ether. This product is intended for research and analytical applications. Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive compound extracted from Eupatorium odoratum. Scutellarein tetramethyl ether exhibits anti-inflammatory, antibacterial, pro-coagulant, and anti-tumor activities. Scutellarein tetramethyl ether exerts its anti-inflammatory effects by modulating the NF-κB pathway and regulates bacterial resistance through the inhibition of efflux pumps. Additionally, Scutellarein tetramethyl ether accelerates coagulation time via the endogenous coagulation pathway. Studies have shown that Scutellarein tetramethyl ether can effectively inhibit the growth of the liver cancer cell line HepG2 (IC50= 20.08 μg/mL).
Reference Standards   Bacterial   COX   NO Synthase   NF-κB  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-W250153A Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.
P2Y Receptor  
Platelet Disease  
/
HY-15284S Prasugrel-d5
Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
Isotope-Labeled Compounds   P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P1702 GR83895
GR83895 is a RGD based peptide, and inhibits ADP-induced platelet aggregation of human gel-filtered platelets (IC50= 0.9 μM).
Integrin  
/
HY-P10868 Pegtarazimod
Pegtarazimod (RLS-0071) is a dual-target anti-inflammatory peptide that exerts its effects by simultaneously regulating the complement system and neutrophil-associated inflammatory pathways. Pegtarazimod reduces ROS production both in vitro and in vivo, and decreases the level of neutrophil elastase, a marker of neutrophil extracellular traps (NETs), in vivo, thereby alleviating inflammatory responses. Pegtarazimod significantly improves the survival rate of mice in multiple in vivo models of acute graft-versus-host disease (aGVHD). Pegtarazimod inhibits the activation of the C1 complex, reduces the herpes zoster-like spread of herpes simplex virus type 1 skin infection, and improves the survival rate of infected mice. Pegtarazimod can be used in research related to acute graft-versus-host disease, acute pulmonary diseases, and skin herpes simplex virus type 1 infection.
Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   HSV Infection  
/
HY-W049802 N-((Allyloxy)carbonyl)-N-methyl-L-alanine
N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-P991211 Bemiltenase alfa
Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia.
Factor XI  
Blood or Cardio-cerebrovascular Disease  
/
HY-P11349 TG-Gln
TG-Gln (a glutamine donor peptide with the sequence H-NQEQVSPLERCG-NH₂) is a substrate-type crosslinker targeting activated coagulation transglutaminase XIII (FXIIIa). TG-Gln is promising for research of angiogenesis induction, cartilage repair, and wound healing.
Biochemical Assay Reagents  
/
HY-167686 Variabilin
Variabilin (Homopisatin) is a potent RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg.
Integrin  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991213 Nonacog gamma
Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B.
Factor XI  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991994 REGN9533
REGN9533 is a human-derived monoclonal antibody against FXII/FXIIa with high affinity for FXII, FXIIa and β-FXIIa. REGN9533 selectively inhibits the intrinsic coagulation pathway and FXIIa-driven plasma kallikrein activity. REGN9533 is applicable to FXIIa-related diseases such as thrombosis and hereditary angioedema.

Species: Human

Factor Xa  
Blood or Cardio-cerebrovascular Disease  
/
HY-13463BS Avatrombopag-d8 hydrochloride
Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.
Isotope-Labeled Compounds   Thrombopoietin Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P992351 ELB021
ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8+ T cell-mediated cytotoxicity. Independent of PD-1 regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection.

Species: Human

Others  
Leukemia/Lymphoma/Myeloma   HIV-1 Infection  
/
HY-122292 Celastramycin A
Celastramycin A is an antibiotic isolated from Streptomyces MaB-QuH-8, which exhibits antimicrobial activity against series of gram-negative bacteria and mycobacteria, with MICs between 0.05-3.1 μg/ml. Celastramycin A exhibits immunosuppressing efficacy in ex vivo Drosophila through immune deficiency pathway (IC50 of 0.008 μg/ml), inhibits the immunoresponse in human innate immunity through TNF-α signaling, inhibits IL-8 production in HUEVCs with IC50 of 0.06 μg/ml.

Source: Drosophila

Antibiotic   Bacterial  
Infection   Inflammation or Immune System Disease  
/
HY-P2291A Beta-defensin 103 isoform X1, pig TFA
Beta-defensin 103 isoform X1, pig TFA is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.
Bacterial  
Inflammation or Immune System Disease  
/
HY-N6714R Alternariol (Standard)
Alternariol (Standard) is the analytical standard of Alternariol. This product is intended for research and analytical applications. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
Reference Standards   Topoisomerase   Androgen Receptor   Estrogen Receptor/ERR   Apoptosis  
Cancer   Infection  
/
HY-182665 Sterile Sodium Citrate Anticoagulant (4%)
Sterile Sodium Citrate Anticoagulant (4%) is a ready-to-use solution that prevents blood clotting by chelating with calcium ions. It is mainly used in experiments such as coagulation tests and erythrocyte sedimentation rate (ESR) measurements.
Biochemical Assay Reagents  
/
HY-P2457 rCRAMP (rat)
rCRAMP (rat) is the rat cathelin-related antimicrobial peptide. rCRAMP (rat) contributes to the antibacterial activity in rat brain peptide/protein extracts. rCRAMP (rat) is a potential key player in the innate immune system of rat CNS.
Bacterial  
Inflammation or Immune System Disease  
/
HY-N12905 Celastramycin A (isomer)
Celastramycin A isomer is an isomer of Celastramycin A (HY-122292), an antibiotic against Gram-negative bacteria and Mycobacterium tuberculosis with an MIC of 0.05-3.1 μg/mL. Celastramycin A exerts immunosuppressive effects in Drosophila ex vivo via the immunodeficiency pathway (IC50 of 8 ng/mL), inhibits human innate immune responses via the TNF-α pathway, and inhibits IL-8 production in HUEVC with an IC50 of 60 ng/mL.

Source: Streptomyces strains

Antibiotic   Bacterial  
/
HY-112935 Nonacog alfa
Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B.
Ser/Thr Protease  
/
HY-15651S Alvelestat-13C,d3
Alvelestat-13C,d3 (AZD9668-13C,d3) is the deuterated, 13C-labeled Alvelestat (HY-15651). Alvelestat (AZD9668) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis.
Isotope-Labeled Compounds   Elastase   Claudin   Interleukin Related   MMP  
Skin Inflammation   Pulmonary Disease   Aneurysm  
/
HY-D2712 Cy3 Dextran (MW 500000)
Cy3 Dextran (MW 500000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm).
Fluorescent Dye  
/
HY-D2460 Dextran-CY5.5
Dextran-CY5.5 is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
Fluorescent Dye  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-N12189 3β-(Acetyloxy)stigmast-5-en-7-one
3β-(Acetyloxy)stigmast-5-en-7-one has anti-complement activity.
Others  
/
HY-P5407 HD5
HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer.
SARS-CoV   Angiotensin-converting Enzyme (ACE)  
Colorectal Cancer   Small Cell Lung Cancer   Epithelial Ovarian Cancer   SARS-CoV-2 Infection   HPV Infection  
/
HY-D2710 Cy3 Dextran (MW 40000)
Cy3 Dextran (MW 40000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm).
Fluorescent Dye  
/
HY-158741 IPG-2 AM
IPG-2 AM (APG-2 Acetoxymethyl ester) is a membrane-permeant acetoxymethyl ester derivative and selective fluorescent potassium ion indicator. IPG-2 AM exhibits fluorescence increases proportional to extracellular potassium ion concentrations. IPG-2 AM enables real-time monitoring of cytosolic free potassium ion fluxes in human platelets and macrophages. IPG-2 AM can be used for the research of intracellular potassium concentration dynamics.
Fluorescent Dye   Potassium Channel  
/
HY-N16463 QS-S2
QS-S2 is the impurity of QS-21 (HY-101092A). QS-21 is an innate immune system-targeted adjuvant.
Drug Intermediate  
/
HY-111582G BBIQ (GMP)
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of  59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-113113S 13,14-Dihydro PGE1-d4
13,14-Dihydro PGE1-d4 (13,14-Dihydroprostaglandin E1-d4) is deuterium labeled 13,14-Dihydro PGE1. 13,14-Dihydro PGE1 is a metabolite of PGE1 (Prostaglandin E1) which inhibits the ADP-induced platelet aggregation (ID50 = 10.8 ng/mL platelet rich plasma).
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-N7314 Asebogenin
Asebogenin has antimalarial activity in vitro. Asebogenin can inhibit the phosphorylation of Syk, thereby effectively suppressing platelet activation and the formation of neutrophil extracellular traps.
Syk  
Inflammation or Immune System Disease  
/
HY-P992152 Vatreptacog alfa
Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia.

Species: Human

Factor VIIa   Drug Derivative  
Blood Disease  
/
HY-W1122690 Vitamin K-d7
Vitamin K-d7 is the deuterium labeled Vitamin K (HY-B2172). Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-D2466 Cy3 Dextran (MW 70000)
Cy3 Dextran (MW 70000) is a fluorescent labeling reagent that conjugates the Cy3 (HY-D0822) fluorescent dye with Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. The maximum emission wavelength of Cy3 is approximately 562-570 nm. Dextran inhibits platelet aggregation and coagulation factors, and serves as a plasma volume expander.
Fluorescent Dye  
Blood or Cardio-cerebrovascular Disease  
/
HY-W250153 Adenosine 3'-phosphate 5'-phosphosulfate lithium
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.
P2Y Receptor  
Platelet Disease  
/
HY-D2707 Cy3 Dextran (MW 5000)
Cy3 Dextran (MW 5000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm).
Fluorescent Dye  
/
HY-D2705 Cy3 Dextran (MW 2000)
Cy3 Dextran (MW 2000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm).
Fluorescent Dye  
/
HY-P991834 Anti-Mouse CD41 Antibody (S-R690)
Anti-Mouse CD41 Antibody (S-R690) reacts with mouse CD41. CD41 is a crucial protein involved in platelet aggregation and hemostasis. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).

Species: Mouse

Integrin  
Cardiovascular Disease  
/
HY-32350S1 Ercalcitriol-d3
Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
Isotope-Labeled Compounds   VD/VDR   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-B1508R Vitamin K4 (Standard)
Vitamin K4 (Standard) is the analytical standard of Vitamin K4. This product is intended for research and analytical applications. Vitamin K4 is a chemically synthesized Vitamin K which plays an important role in the normal blood coagulation system. Vitamin K4 arrests the cells in S phase and induces apoptosis. Vitamin K4 can be used for the research of cancer, such as prostate cancer and osteosarcoma.
Reference Standards   Endogenous Metabolite   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-W653896 Alternariol-d2
Alternariol-d2 is deuterium labeled Alternariol. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
Isotope-Labeled Compounds   Topoisomerase   Apoptosis   Androgen Receptor   Estrogen Receptor/ERR  
Infection  
/
HY-D2421 DEAE-dex-Cy5
DEAE-dex-Cy5 is a fluorescent labeling reagent that combines Cy5 (HY-D0821) fluorescent dye, Dextran (dex) and Diethylaminoethyl (DEAE). Cy5 is a Cyanine dye (with a long wavelength about 662nm) that can be used for molecular labeling and microscopy imaging. Dex has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
Fluorescent Dye  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-139133 L-NASPA
L-NASPA is a ophosphatidic acid (LPA) inhibitor useful in the study of platelet activation.
LPL Receptor  
Inflammation or Immune System Disease  
/
HY-W777681 Triflusal-13C6
Triflusal-13C6 is a C13-labeled Triflusal. Triflusal is a platelet aggregation inhibitor.
Isotope-Labeled Compounds  
/
HY-137431S Asundexian-d3
Asundexian-d3 (BAY-2433334-d3) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM.
Isotope-Labeled Compounds   Factor Xa  
/
HY-P2076A Dusquetide TFA
Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
p62   Bacterial  
Infection  
/
HY-P991029 Sutacimig
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia.

Species: Human

Thrombin   Ser/Thr Protease   TREM receptor  
Platelet Disease  
/
HY-P1398 Compstatin control peptide
Compstatin control peptide is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor.
Complement System  
Inflammation or Immune System Disease  
/
HY-144002 RIBI-529
RIBI-529 (RC-529) is a fully synthetic, low-toxicity TLR4 agonist vaccine adjuvant. RIBI-529 upregulates cell surface co-stimulatory molecules, receptors, cytokines and chemokines, and activates the innate immune system. RIBI-529 enhances short-term CD4+ T cell clonal expansion, division, and ex vivo survival under growth factor withdrawal conditions. RIBI-529 enhances humoral and cell-mediated adaptive immune responses, induces non-specific resistance against viral and bacterial pathogens, and skews responses toward a Th1 type, accompanied by Th2 responses.
Toll-like Receptor (TLR)   Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P1798 Platelet Factor 4 (58-70), human
Platelet Factor 4 (58-70), human, a peptide based on the amino acid sequence corresponding to residues 58-70 of platelet factor-4 (PF-4), contains the major heparin-binding domain, which is not sufficient for full antiangiogenic activity.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P99769 Omfiloctocog alfa
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A.
Factor VIII  
Metabolic or Endocrine Disease  
/
HY-125053A Batifiban TFA
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3.
Glycoprotein VI  
Blood or Cardio-cerebrovascular Disease  
/
HY-P992102 Ascuprubart
Ascuprubart is an anti-human monoclonal antibody targeting Complement C5.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-15284S1 Prasugrel-d3
Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991792 Anti-Rat pan-CD45 Antibody (OX1)
Anti-Rat pan-CD45 Antibody (OX1) reacts with a common epitope present on all isotypes of rat CD45. CD45 is largely expressed in the lymphoid system, but it is also found in all hematopoietic cells except erythrocytes and platelets. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Rat

Phosphatase  
/
HY-N2996 Ganodermanondiol
Ganodermanondiol is a melanogenesis inhibitor isolated from the Ganoderma lucidum.Ganodermanondiol exhibits potent cytoprotective effects on tert-butyl hydroperoxide-induced hepatotoxicity. Ganodermanondiol shows significant anti-HIV-1 protease activity with an IC50 of 90 μM. Ganodermanondiol exhibits a strong anticomplement activity against the classical pathway of the complement system with an IC50 of 41.7μM.
HIV Protease  
Infection  
/
HY-P4332 Boc-Glu(OBzl)-Ala-Arg-AMC
Boc-Glu(OBzl)-Ala-Arg-AMC is a fluorogenic substrate for coagulation factor XIa and trypsin. The cleavage of the amide bond between arginine and the methylcoumarin amide group releases fluorescent 7-Amino-4-methylcoumarin (HY-D0027).
Fluorescent Dye   Ser/Thr Protease  
Blood or Cardio-cerebrovascular Disease  
/
HY-N7401 Entadamide-A-β-D-glucopyranoside
Entadamide-A-β-D-glucopyranoside is one of the major components in the seeds of Entada phaseoloides. Entadamide-A-β-D-glucopyranoside has anti-complement activitie.
Complement System  
Autoimmune Disease  
/
HY-N8218 Homoeriodictyol 7-O-β-D-glucoside
Homoeriodictyol 7-O-β-D-glucoside is a natural platelet-activating factor (PAF) antagonist. Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC50 of 0.8 μM.
Platelet-activating Factor Receptor (PAFR)  
Blood or Cardio-cerebrovascular Disease  
/
HY-P99709 Lodapolimab
Lodapolimab (LY3300054) is a fully human IgG1λ anti-PD-L1 monoclonal antibody, with an EC50 of 0.075 nM against hPD-L1 and an EC50 of 0.085 nM against cynomolgus monkey PD-L1. Lodapolimab induces naive T cell activation, enhances the T cell activation effect of anti-CTLA4 antibodies, promotes anti-tumor alloreactivity, regulates innate immune pathways, and induces characteristics of adaptive immune activation. Lodapolimab can be used in research related to high-grade serous ovarian cancer and other solid tumors.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease   Ovarian Cancer   Triple-Negative Breast Cancer  
/
HY-P4331 Boc-Gln-Gly-Arg-AMC
Boc-Gln-Gly-Arg-AMC is a fluorogenic substrate for kallikrein (PKa), coagulation factor XIIa (FXIIa) and coagulation factor XIa (FXIa). Boc-Gln-Gly-Arg-AMC enables fluorescence-based activity assays for PKa, FXIIa and FXIa.
Fluorescent Dye   Ser/Thr Protease  
Blood or Cardio-cerebrovascular Disease  
/
HY-D2709 Cy3 Dextran (MW 20000)
Cy3 Dextran (MW 20000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm).
Fluorescent Dye  
/
HY-114128 Turoctocog alfa pegol
Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A.

Species: Human

Factor VIII  
/
HY-P990378 Anti-Complement Factor P/Properdin Antibody
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-W105875 Iron(II) D-gluconate dihydrate, 98%
Iron(II) D-gluconate dihydrate, 98% is used for blood coagulation.
Biochemical Assay Reagents  
/
HY-D2708 Cy3 Dextran (MW 10000)
Cy3 Dextran (MW 10000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm).
Fluorescent Dye  
/
HY-N7097 Sulbenicillin disodium
Sulbenicillin disodium is a semisynthetic α-sulfonylbenzylpenicillin antibiotic. Sulbenicillin disodium exerts antibacterial activity against multiple gram-negative rods. Sulbenicillin disodium inhibits primary and secondary platelet aggregation, serotonin release from platelets, and platelet adherence via platelet surface coating. Sulbenicillin disodium can be used for the research of Pseudomonas aeruginosa, Pseudomonas maltophilia, and Pseudomonas cepacia infections.
Antibiotic   Bacterial  
Pseudomonas Aeruginosa Infection  
/
HY-NP0194C C1q Protein (rat)
C1q Protein (rat) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rat) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rat) can be used for the research of mutiple disease.
Complement System  
Inflammation or Immune System Disease  
/
HY-W145481A D-Galacto-D-mannan
D-Galacto-D-mannan (Carob galactomannan) is an orally active Dectin-2 agonist. D-Galacto-D-mannan exerts antioxidant activity against hydroxyl radical generation. D-Galacto-D-mannan activates Dectin-2 to trigger downstream signaling pathways, promote the expression of immunoregulatory molecules, coordinate innate and adaptive immune responses, and inhibit excessive inflammatory responses by upregulating the expression of Sirtuin 1. When used as a vaccine adjuvant, D-Galacto-D-mannan induces cellular and humoral immune responses, promotes IFNγ secretion, increases antibody levels and virus neutralization titers, and elevates the levels of immunoglobulin G and A. D-Galacto-D-mannan can serve as an adjuvant for foot-and-mouth disease vaccines, enhance the vaccine-mediated ability of hosts to defend against viral infection in mice, and reduce local side effects at the inoculation site in pigs. D-Galacto-D-mannan can be used in the research of inflammatory and immune diseases, such as foot-and-mouth disease.
C-type Lectin-like Receptors (CTLRs)   Sirtuin  
Inflammation or Immune System Disease  
/
HY-P2320 IDR-1
IDR-1 is an antimicrobial peptide that is active against Gram-positive and Gram-negative bacteria. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities. IDR-1 has anti-inflammatory and anti-infective properties, enhances the levels of monocyte chemokines, and attenuates pro-inflammatory cytokine release.
Bacterial  
Inflammation or Immune System Disease  
/
HY-P99767 Olendalizumab
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus.

Species: Human

Complement System  
Infection  
/
HY-P991401 GSK2862277
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-N0684S Vitamin K1-d7
Vitamin K1-d7 is the deuterium labeled Vitamin K1. Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.
Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991513 BI-655064
BI-655064, a humanised anti-CD40 antibody with has fragment crystallisable (Fc) regions with two mutations that prevent Fc-mediated antibody-dependent or complement-mediated cellular cytotoxicity and platelet activation. BI-655064 can be used for the study of autoimmune disease, such as lupus nephritis and rheumatoid arthritis (RA).

Species: Human

TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P99298 Lampalizumab
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-P990782 Efzofitimod
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD).

Species: Human

Aminoacyl-tRNA Synthetase  
Inflammation or Immune System Disease  
/
HY-B2123R Lactose (Standard)
Lactose (Standard) is the analytical standard of Lactose. This product is intended for research and analytical applications. Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions.
Reference Standards   Endogenous Metabolite   Interleukin Related   ERK   NF-κB  
Inflammation or Immune System Disease  
/
HY-P99928 Efprezimod alfa
Efprezimod alfa (MK 7110; CD24 Fc) is a humanized CD24-Fc fusion protein. Efprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, inhibiting the activation of antigen-presenting cells and subsequent inflammatory responses. Efprezimod alfa is applicable to the research of acute graft-versus-host disease and acquired immunodeficiency syndrome.
Transmembrane Glycoprotein  
Cancer  
/
HY-P10887 Pegevongitide
Pegevongitide (AV-001) is a Tie2 agonist. Pegevongitide resists the increased endothelial cell permeability induced by SARS-CoV-2 infection. Pegevongitide activates the angiogenin (angiogenin)/Tie2 signaling pathway. Pegevongitide reduces perivascular space dilation and upregulates perivascular Aquaporin-4 expression. Pegevongitide decreases the expression of TNF-α, PAI-1, CXCL9 and P-selectin, improves white matter integrity, enhances cognitive function and exerts neuroprotective effects. Pegevongitide improves white matter integrity in middle-aged rats with vascular dementia induced by multiple microinfarctions. Pegevongitide can be used in related research on diseases such as COVID-19 and vascular dementia.
Tie   ANGPTL   SARS-CoV   Aquaporin   TNF Receptor   PAI-1   CXCR   P-selectin  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   SARS-CoV-2 Infection  
/
HY-N0684S3 Vitamin K1-13C6
Vitamin K1-13C6 is the 13C-labeled Vitamin K1. Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.
Isotope-Labeled Compounds  
Blood or Cardio-cerebrovascular Disease  
/
HY-W047191 D-Glucono-1,4-lactone
D-Glucono-1,4-lactone is a derivative of D-gluconic acid (HY-Y0569C). D-Glucono-1,4-lactone can be isolated from fruits, vegetables, honey, kombucha and wine. D-Glucono-1,4-lactone inhibits thrombin-induced arachidonic acid peroxidation and platelet activation. D-Glucono-1,4-lactone reduces superoxide anion production in thrombin-activated platelets. D-Glucono-1,4-lactone exerts antioxidant activity on platelets under oxidative stress conditions and prevents excessive platelet activation through antioxidant mechanisms. D-Glucono-1,4-lactone can be used in research related to cardiovascular diseases.
Drug Derivative  
Platelet Disease  
/
HY-N0684R Vitamin K1 (Standard)
Vitamin K1 (Standard) is the analytical standard of Vitamin K1. This product is intended for research and analytical applications. Vitamin K1 a naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.
Reference Standards  
Blood or Cardio-cerebrovascular Disease  
/
HY-D0199R Adenosine 5'-diphosphate disodium (Standard)
Adenosine 5'-diphosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-diphosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis.
Endogenous Metabolite   Reference Standards  
Blood or Cardio-cerebrovascular Disease  
/
HY-148748G Butyzamide (GMP)
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay.
JAK   STAT   p38 MAPK  
Blood or Cardio-cerebrovascular Disease  
/
HY-N1717 2-Acetylbenzoic acid
2-Acetylbenzoic acid, a Benzoic acid (HY-N0216) derivative, is a weak platelet aggregation inhibitor. 2-Acetylbenzoic acid inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation.
Platelet-activating Factor Receptor (PAFR)  
Cardiovascular Disease  
/
HY-P6442 Chemerin15
Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury.
Chemerin Receptor   Syk   ERK   Src   p38 MAPK   P-selectin  
Cerebrovascular Disease   Cardiovascular Disease   Ischemia-Reperfusion Injury  
/
HY-P99443 Aselizumab
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma.

Species: Human

P-selectin  
Inflammation or Immune System Disease  
/
HY-N10530 Lactodifucotetraose
Lactodifucotetraose is a difucosylated human milk oligosaccharide. Lactodifucotetraose inhibits platelet function and the release of inflammatory factors. Lactodifucotetraose can be used for the research of *Campylobacter jejuni*-associated diarrhea and platelet-induced inflammatory processes.

Source: human milk

Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-112486G TA-316 (GMP)
TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist.
Cyclin G-associated Kinase (GAK)  
Blood or Cardio-cerebrovascular Disease  
/
HY-Y0320GL Dimethyl sulfoxide (GMP Like)
Dimethyl sulfoxide (DMSO) (GMP Like) is the GMP Like class Dimethyl sulfoxide (HY-Y0320C). Dimethyl sulfoxide is an aprotic solvent that can dissolve water-insoluble therapeutic and toxic agents. Dimethyl sulfoxide has a strong affinity for water and has the ability to rapidly penetrate or enhance the penetration of other substances through biological membranes. Dimethyl sulfoxide also has potential free radical scavenging and anticholinesterase effects and may affect coagulation activity. Dimethyl sulfoxide also induces histamine release from mast cells but is thought to have low systemic toxicity.
Cholinesterase (ChE)   Bacterial  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-N2101 Benzoyloxypaeoniflorin
Benzoyloxypaeoniflorin, isolated from the root of Paeonia suffruticosa, is a tyrosinase inhibitor against mushroom tyrosinase with IC50 of 0.453 mM. Benzoyloxypaeoniflorin is NF-κB Inhibitor and contributes to improving blood circulation through its inhibitory effect on both platelet aggregation and blood coagulation.
Tyrosinase   NF-κB  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity  
/
HY-P99484 Botensilimab
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer.

Species: Human

CTLA-4  
Non-Small Cell Lung Cancer  
/
HY-P99358 Dezamizumab
Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis.

Species: Human

Complement System  
Inflammation or Immune System Disease  
/
HY-N1464A Aristolone
Aristolone is a sesquiterpene that can be isolated from Aristolochia debilis, Rosmarinus officinalis and Ficus Auriculata. Aristolone in Ara Fruit can be used as a prediction of apoptosis in HeLa cells. Aristolone inhibits the C1 complement component. Aristolone produces cytotoxicity effects on cells. Aristolone has anticancer properties and can be studied in research for cervical cancer.
Complement System   Apoptosis  
Cancer   Digestive System Disease   Autoimmune Disease   Digestive System Inflammation  
/
HY-101092A QS-21
QS-21 is a mixture of QS-21-Xyl (HY-101092B) and QS-21-Api (HY-101092), with a ratio of 35:65. QS-21 is an innate immune system-targeted adjuvant. QS-21 is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria).
Toll-like Receptor (TLR)  
Cancer   Infection  
/
HY-132828 Odatroltide
Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities.
P-selectin  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-159114 Whole Glucan Particles
Whole Glucan Particles is a Dectin-1a agonist. Whole Glucan Particles activates the innate immune system to improve the function of macrophages, monocytes and other immune cells.
C-type Lectin-like Receptors (CTLRs)   Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-D0996 LDS-751
Lds-751 is a nucleic acid stain that mainly detects DNA. Lds-751 is a nucleic acid stain that mainly detects DNA. Lds-751 has a high affinity for DNA and fluorescence is enhanced after binding, but the maximum emission wavelength is 670nm. Lds-751 and Thiazole orange can be used for the differentiation of red blood cells, platelets, reticulocytes, and nucleated cells and can be stimulated at 488nm. Studies have shown that LDS-751 binds almost exclusively to mitochondria when incubated with nucleated living cells. After nucleated Acridine Orange (HY-101879) staining and LDS-751 treatment of cells, confocal microscopy revealed almost no co-location of the cells. Staining with Rhodamine 123 (HY-D0816), a dye known to bind polarized mitochondria, was almost identical to the pattern observed with LDS-751.
DNA Stain  
/
HY-P99786 Pozelimab
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases.

Species: Human

Complement System  
Metabolic or Endocrine Disease  
/
HY-W127502 1-Hexadecyl lysophosphatidic acid
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.
Biochemical Assay Reagents  
/
HY-NP0196 Mouse immunoglobulin G
Mouse Immunoglobulin G (Mouse IgG) is the most abundant glycoprotein in mouse serum, which bridges innate and adaptive immune responses. A conserved asparagine-297 residue on each heavy chain contains an N-linked glycosylation site. Mouse Immunoglobulin G shares many glycosylation features with human IgG, but contains N-Glycolylneuraminic acid (HY-128965) instead of N-acetylneuraminic acid (HY-I0400). Mouse Immunoglobulin G is widely used as a negative isotype control, immunoassay coating protein and research standard in the life sciences.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-N6714 Alternariol
Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.

Source: fungi of the genus Alternaria

Topoisomerase   Androgen Receptor   Estrogen Receptor/ERR   Apoptosis  
Infection  
/
HY-W027544 MCA
MCA (7-Methoxycoumarin-4-acetic acid) is a Coumarin (HY-N0709) derivative. MCA quantitates platelet-activating factor (PAF) by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities.
Fluorescent Dye  
/
HY-P3151 Gliadin p31-43
Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research.
Others  
Inflammation or Immune System Disease  
/
HY-P99791 Orilanolimab
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P99759 Nogapendekin alfa (his tag)
Nogapendekin alfa his tag is an immunostimulant that binds to the IL-2RβγC complex on immune cells. Nogapendekin alfa his tag stimulates the proliferation and activation of natural killer cells and CD8+ T cells, upregulates the expression of granzyme B and perforin, and activates the innate and adaptive immune branches. Nogapendekin alfa his tag forms ALT-803 with IL-15RαSuFc; this complex has an extended biological half-life, improved biodistribution and retention in lymphoid tissues, enhances natural killer cell-mediated rituximab-dependent cellular cytotoxicity, and reduces tumor burden and improves survival when combined with anti-CD20 monoclonal antibody therapy. Nogapendekin alfa his tag can be used in the research of non-Hodgkin's lymphoma.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Non-Hodgkin Lymphoma  
/
HY-P2076 Dusquetide
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
p62   Bacterial  
Infection  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-P991127 Claseprubart
Claseprubart (DNTH103) is an inhibitor targeting C1s of the complement system and an inhibitor of the C1 component of the complement cascade. Claseprubart is in phase 2 clinical evaluation. Claseprubart has application potential in research related to multifocal motor neuropathy and generalized myasthenia gravis.

Species: Human

Complement System  
Myasthenia gravis  
/
HY-P99450 Avdoralimab
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research.

Species: Human

Complement System  
Cancer   Inflammation or Immune System Disease  
/
HY-B0665 Fibrin
Fibrin is an insoluble protein found in blood that is produced in response to bleeding. As the main component of blood clots, fibrin functions in blood coagulation. Fibrin binds to the integrins ICAM-1, VE-cadherin, αIIbβ3, αMβ2, αvβ3 and α5β1. Fibrin is used in research related to chronic wounds.

Source: bovine blood

Integrin  
Blood Disease  
/
HY-NP0194A C1q Protein (mouse)
C1q Protein (mouse) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (mouse) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (mouse) can be used for the research of mutiple disease.
Complement System  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-134222A N-Acetylserine
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third complement protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of C3b via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification.
Endogenous Metabolite   Complement System  
/
HY-P99313 Quilizumab
Quilizumab (Anti-Human IGHE Recombinant Antibody; 47H4; MEMP1972A) is a monoclonal antibody that targets FcγRIIIa and the M1 prime segment of human membrane-bound IgE. Quilizumab has enhanced FcγRIIIa binding affinity and activity against IgE class-switched B cells, and reduces serum IgE levels by inducing antibody-dependent cell-mediated cytotoxicity and apoptosis through cross-linking of membrane-bound IgE receptors. Quilizumab depletes IgE-producing cells; it also directly binds the membrane-bound M1 prime domain on IgE class-switched cells to inhibit IgE production. Quilizumab is used in research on allergic asthma and allergic diseases (asthma, allergic rhinitis).

Species: Human

Drug Derivative   Fc Receptor (FcR)   Apoptosis  
Allergic Rhinitis   Asthma  
/
HY-P9922 Olaratumab
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity.

Species: Human

PDGFR  
Prostate Cancer   Non-Small Cell Lung Cancer   Metastatic Pancreatic Cancer   Glioblastoma Multiforme  
/
HY-B2172 Vitamin K
Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.

Source: Widespread

Endogenous Metabolite  
Cancer   Cardiovascular Disease   Glucose Metabolism  
/
HY-P99125 Anti-Mouse CD16/CD32 Antibody (2.4G2)
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders.

Species: Mouse

Fc Receptor (FcR)  
Autoimmune Disease   Atherosclerosis  
/
HY-P990091 Riliprubart
Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

Complement System   Fc Receptor (FcR)  
Neurological, Eye or Ear Disease   Systemic Lupus Erythematosus  
/
HY-NP004 Cobra Venom Factor
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.).
Complement System  
Inflammation or Immune System Disease   Pulmonary Disease  
/
HY-P99415 Abelacimab
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies.

Species: Human

Factor Xa  
Blood or Cardio-cerebrovascular Disease  
/
HY-P99396 Spesolimab
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-W145519 Hydroxyethyl starch (MW170-230 kDa)
Hydroxyethyl starch (MW170-230 kDa) is a type of hydroxyethyl starch with a molecular weight of 170-230 kDa. A medium-molecular-weight hydroxyethyl starch (HES 200/0.62) exhibits minimal intravascular hydrolysis. The rapidly degradable medium-molecular-weight Hydroxyethyl starch 200/0.5 causes almost no coagulation disorders and improves hemorheological parameters.
Environmental Pollutants   Biochemical Assay Reagents  
Blood Disease  
/
HY-P99009 Batoclimab
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease.

Species: Human

Fc Receptor (FcR)  
Autoimmune Disease  
/
HY-147305 Efgartigimod alfa
Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research.

Species: Human

Fc Receptor (FcR)  
Myasthenia gravis   Platelet Disease  
/
HY-P7787 Coagulation factor III/F3 Protein, Human (HEK293, His)
Coagulation factor III/F3 Protein, Human (HEK293, His) is a recombinant human CD142 expressed in HEK 293 cells with a His tag at the C-terminus. Coagulation Factor III/CD142 Protein is a principal regulator of oncogenic neoangiogenesis and controls therefore the cancerous process.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins Tissue Factor/CD142

/
HY-P74371 C7/Complement component C7 Protein, Human (HEK293, His, solution)
C7, also known as complement component C7 protein, is a key component of the membrane attack complex (MAC) and plays a key role in innate and adaptive immune responses. As a component of MAC, C7 actively participates in the formation of target cell plasma membrane pores. C7/Complement component C7 Protein, Human (HEK293, His, solution) is the recombinant human-derived C7/Complement component C7 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 7

/
HY-P74373 C6/Complement component C6 Protein, Human (HEK293, His)
C6/Complement component C6 Protein is a part of the lytic membrane attack complex formed during complement activation, which has an indispensable role in innate and acquired immune responses by forming pores in the plasma membrane of target cells, as well as cancer immune surveillance. It is a component of the complement cascade which can be incorporated into the cell membrane and cause cell lysis. People with C6 deficiency are prone to bacterial infection. C6/Complement component C6 Protein, Human (HEK293, His) is the recombinant human-derived C6/Complement component C6 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 6

/
HY-P74374 C2/Complement C2 Protein, Mouse (HEK293, His)
Complement C2 is a component of the classical pathway of the complement system and is cleaved by activated factor C1, resulting in the formation of two distinct fragments: C2b and C2a. The subsequent serine protease activity of C2a is critical for its subsequent interaction with the complement factor C4b, leading to the formation of C3 or C5 convertase. C2/Complement C2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Complement System Complement Component 2

/
HY-P74371A C7/Complement component C7 Protein, Human (HEK293, C-10*His)
C7, also known as complement component C7 protein, is a key component of the membrane attack complex (MAC) and plays a key role in innate and adaptive immune responses. As a component of MAC, C7 actively participates in the formation of target cell plasma membrane pores. C7/Complement component C7 Protein, Human (HEK293, C-10*His) is the recombinant human-derived C7/Complement component C7 protein, expressed by HEK293, with C-10*His labeled tag.

Species: Human; Source: HEK293

/
HY-P74372 C7/Complement component C7 Protein, Human (HEK293, Fc)
C7, also known as complement component C7 protein, is a key component of the membrane attack complex (MAC) and plays a key role in innate and adaptive immune responses. As a component of MAC, C7 actively participates in the formation of target cell plasma membrane pores. C7/Complement component C7 Protein, Human (HEK293, Fc) is the recombinant human-derived C7/Complement component C7 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 7

/
HY-P72944 Coagulation Factor II/F2 Protein, Mouse (HEK293, His)
Coagulation Factor II/F2, also known as thrombin, functions as a pivotal serine protease. Its enzymatic action involves cleaving bonds after Arg and Lys residues, facilitating the conversion of fibrinogen to fibrin. Thrombin additionally activates key factors like V, VII, VIII, XIII, and, in conjunction with thrombomodulin, protein C. Beyond blood homeostasis, thrombin plays a role in inflammation and the complex dynamics of wound healing. Coagulation Factor II/F2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor II/F2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P7787A Coagulation factor III/F3 Protein, Human (HEK293, Fc)
Coagulation factor III/F3 Protein, Human (HEK293, Fc) is a recombinant human CD142 expressed in HEK 293 cells with a Fc tag at the C-terminus. Coagulation Factor III/CD142 Protein is a principal regulator of oncogenic neoangiogenesis and controls therefore the cancerous process.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins Epithelial cell CD Proteins Tissue Factor/CD142

/
HY-P705312 Complement C9 Protein, Human (His, Myc)

Species: Human; Source: E. coli

Complement System Complement Component 9

/
HY-P72189 Coagulation Factor XII/F12 Protein, Pig (His)
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (His) is the recombinant pig-derived Coagulation Factor XII/F12 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Pig; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P73045 Coagulation Factor VII/F7 Protein, Mouse (CHO, His)
Coagulation Factor VII (F7) protein lacks crucial conserved residue(s) needed for propagating feature annotation. Coagulation Factor VII/F7 Protein, Mouse (CHO, His) is the recombinant mouse-derived Coagulation Factor VII/F7 protein, expressed by CHO , with C-His labeled tag.

Species: Mouse; Source: CHO

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P74376 C2/Complement C2 Protein, Human (HEK293, Fc)
C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, Fc) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Complement System Complement Component 2

/
HY-P74241 Coagulation Factor II/F2 Protein, Rat (HEK293, His)
The factor II/F2 protein (also known as thrombin) plays a key role in blood homeostasis, inflammation, and wound healing. As a multifunctional enzyme, it catalyzes the conversion of fibrinogen into fibrin to form the coagulation network. Coagulation Factor II/F2 Protein, Rat (HEK293, His) is the recombinant rat-derived Coagulation Factor II/F2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rat; Source: HEK293

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P700565 Coagulation factor VII/F7 Protein, Human (His-SUMO)
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation factor VII/F7 Protein, Human (His-SUMO) is the recombinant human-derived Coagulation factor VII/F7 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P700599 Coagulation Factor XII/F12 Protein, Pig (P. pastoris, His)
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (P. pastoris, His) is the recombinant pig-derived F12/Coagulation Factor XII, Pig, expressed by P. pastoris , with N-6*His labeled tag.

Species: Pig; Source: P. pastoris

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P700695 Coagulation Factor III/F3 Protein, Canine (HEK293, His)
Coagulation Factor III (F3), or Tissue Factor (TF), initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex critically activates factors IX or X through limited proteolysis, initiating the coagulation cascade on the cell surface. F3's interaction with HSPE, inhibited by heparin, promotes the generation of activated factor X, emphasizing its central role in regulating hemostatic processes. Coagulation Factor III/F3 Protein, Canine (HEK293, His) is the recombinant canine-derived Coagulation Factor III/F3 protein, expressed by HEK293 , with C-His labeled tag.

Species: Canine; Source: HEK293

Enzymes & Regulators Hydrolases (EC 3)

/
HY-P700697 C2/Complement C2 Protein, Cynomolgus (HEK293, His)
Complement C2 is a component of the classical pathway of the complement system and is cleaved by activated factor C1, resulting in the formation of two distinct fragments: C2b and C2a. The subsequent serine protease activity of C2a is critical for its subsequent interaction with the complement factor C4b, leading to the formation of C3 or C5 convertase. C2/Complement C2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

Complement System Complement Component 2

/
HY-P705191 C2/Complement C2 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi)

Species: Cynomolgus; Source: HEK293

Complement System Biotinylated Proteins Complement Component 2

/
HY-P82726 Tissue Factor Antibody (YA2471)
Tissue Factor Antibody (YA2471) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Tissue Factor.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80577 C3 Antibody (YA575)
C3 Antibody (YA575) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C3.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85912 Factor XIIIa Antibody (YA5604)
Factor XIIIa Antibody (YA5604) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Factor XIIIa.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P85156 Factor VIII Antibody
Factor VIII Antibody (YA4848) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Factor VIII.

Host: Rabbit; Reactivity: Human, Mouse

Polyclonal Antibodies Primary Antibodies

/
HY-P810367 Complement factor B Antibody
Complement factor B Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Complement factor B.

Host: Rabbit; Reactivity: Human, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P80577A C3 Antibody (YA575)(PBS only)
C3 Antibody (YA575) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C3.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81243 F2 Antibody
F2 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to F2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81468 C1QA Antibody (YA1213)
C1QA Antibody (YA1213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C1QA.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81468A C1QA Antibody (YA1213)(PBS only)
C1QA Antibody (YA1213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C1QA.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81608 Factor IX Antibody (YA1353)
Factor IX Antibody (YA1353) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Factor IX.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83239 Complement factor B Antibody (YA2984)
Complement factor B Antibody (YA2984) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Complement factor B.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86034 Factor XIIIa Antibody (YA5726)
Factor XIIIa Antibody (YA5726) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Factor XIIIa.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P86517 Adiponectin Antibody (YA6209)
Adiponectin Antibody (YA6209) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Adiponectin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86840 Complement C5 Antibody (YA6533)
Complement C5 Antibody (YA6533) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Complement C5.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P87384 C7 Antibody (YA7067)
C7 Antibody (YA7067) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C7.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P89635 Factor V Antibody (YA8979)
Factor V Antibody (YA8979) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Factor V.

Host: Mouse; Reactivity: human

Monoclonal Antibodies Primary Antibodies

/
HY-P810760 Factor IX Antibody (YA10003)
Factor IX Antibody (YA10003) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to Factor IX.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811174 Factor VII Antibody
Factor VII Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Factor VII.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-K0253 Heparin Agarose 6FF

MCE Heparin Agarose 6FF is suitable for the separation and purification of heparin-binding biomolecules, including antithrombin III, coagulation factors, other plasma proteins, DNA-binding proteins, lipoproteins, protein synthesis factors, nucleic acid-related enzymes, and steroid receptors.

Protein Biology Protein Purification Agarose Beads

/
HY-K0254 Blue Agarose 6FF

MCE Blue Agarose 6FF can be used for the purification of biological macromolecules such as albumin, interferons, nucleotide-dependent enzymes (e.g., kinases, dehydrogenases), α2-macroglobulin, and coagulation factors.

Protein Biology Protein Purification Agarose Beads

/
HY-K1105A One Step Colored Rapid Gel Preparation Kit (12.5%)

MCE One Step Colored Rapid Gel Preparation Kit (12.5%) uses pre-mixed formulations of the upper gel and lower gel. Simply mix the reagents in pairs, add modified coagulation agent, and the gel will form quickly and easily.

Protein Biology Protein Electrophoresis & WB Gel Preparation Kit

/

Keywords

thromboinflammation | immunothrombosis | coagulation | platelets | innate immunity | complement | neutrophil extracellular traps | cardiovascular thrombosis